2seventy bio Inc. (TSVT): Price and Financial Metrics

2seventy bio Inc. (TSVT): $5.38

0.42 (+8.47%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add TSVT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#155 of 363

in industry

TSVT Price/Volume Stats

Current price $5.38 52-week high $12.69
Prev. close $4.96 52-week low $1.53
Day low $4.80 Volume 1,097,500
Day high $5.40 Avg. volume 1,478,630
50-day MA $4.86 Dividend yield N/A
200-day MA $5.17 Market Cap 276.05M

TSVT Stock Price Chart Interactive Chart >

TSVT POWR Grades

  • Value is the dimension where TSVT ranks best; there it ranks ahead of 77.68% of US stocks.
  • TSVT's strongest trending metric is Growth; it's been moving down over the last 26 weeks.
  • TSVT's current lowest rank is in the Sentiment metric (where it is better than 0.49% of US stocks).

TSVT Stock Summary

  • TSVT's went public 2.16 years ago, making it older than just 2.86% of listed US stocks we're tracking.
  • Revenue growth over the past 12 months for 2SEVENTY BIO INC comes in at 184.07%, a number that bests 97.27% of the US stocks we're tracking.
  • The volatility of 2SEVENTY BIO INC's share price is greater than that of 94.07% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to 2SEVENTY BIO INC are MRSN, BOLT, IPSC, CRBU, and MRUS.
  • To check out 2SEVENTY BIO INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001860782.

TSVT Valuation Summary

  • TSVT's EV/EBIT ratio is -2.1; this is 114.38% lower than that of the median Healthcare stock.
  • TSVT's price/sales ratio has moved down 1.7 over the prior 26 months.

Below are key valuation metrics over time for TSVT.

Stock Date P/S P/B P/E EV/EBIT
TSVT 2023-12-29 1.5 0.7 -1.2 -2.1
TSVT 2023-12-28 1.6 0.8 -1.3 -2.2
TSVT 2023-12-27 1.5 0.7 -1.2 -2.1
TSVT 2023-12-26 1.4 0.7 -1.1 -2.0
TSVT 2023-12-22 1.4 0.7 -1.1 -2.0
TSVT 2023-12-21 1.3 0.6 -1.1 -2.0

2seventy bio Inc. (TSVT) Company Bio


2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.


TSVT Latest News Stream


Event/Time News Detail
Loading, please wait...

TSVT Latest Social Stream


Loading social stream, please wait...

View Full TSVT Social Stream

Latest TSVT News From Around the Web

Below are the latest news stories about 2SEVENTY BIO INC that investors may wish to consider to help them evaluate TSVT as an investment opportunity.

Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3

PRINCETON, N.J., & CAMBRIDGE, Mass., December 12, 2023--Abecma Delivers Sustained Progression-Free Survival Vs. Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma....

Yahoo | December 12, 2023

2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)

CAMBRIDGE, Mass., December 11, 2023--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call on Tuesday, December 12, 2023, at 8:00am ET. The event will highlight data presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 9-12, 2023, in San Diego.

Yahoo | December 11, 2023

2seventy bio Reiterates Commitment to Maximizing Shareholder Value

CAMBRIDGE, Mass., December 06, 2023--2seventy bio, Inc. (NASDAQ: TSVT), ("2seventy" or "the Company"), a leading immuno-oncology cell therapy company, today issued the following statement reiterating its commitment to maximizing shareholder value:

Yahoo | December 6, 2023

Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

PRINCETON, N.J. & CAMBRIDGE, Mass., November 20, 2023--BMS and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel)....

Yahoo | November 20, 2023

3 Biotech Stocks With Key Catalysts Coming in December

Some of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner.

Ian Cooper on InvestorPlace | November 15, 2023

Read More 'TSVT' Stories Here

TSVT Price Returns

1-mo -9.73%
3-mo 26.00%
6-mo 37.24%
1-year -46.09%
3-year N/A
5-year N/A
YTD 26.00%
2023 -54.43%
2022 -63.44%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!